Skip to content

Research on the Preparation Development, Pharmacodynamic Mechanism and Clinical Application of Yanluotong Formula in the Treatment of Retinal Vein Occlusion

Research on the Preparation Development, Pharmacodynamic Mechanism and Clinical Application of Yanluotong Formula in the Treatment of Retinal Vein Occlusion

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001112
Enrollment
Unknown
Registered
2026-04-28
Start date
2025-01-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Vein Occlusion

Interventions

Control Group:Ranibizumab injection
Observation Group(Yanluotong Granules ):treated with Yanluotong Granules in addition to the basic treatment of the control group
Observation Group (Yanluotong Mixture):received treatment with Yanluotong Mixture in addition to the therapy of the control group

Sponsors

Jiaxing Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria for RVO in Ophthalmology, and fundus fluorescein angiography (FFA) confirms RVO with macular edema (RVO-ME); Meet the syndrome differentiation standard for intermingled phlegm and blood stasis in Guidelines for the Diagnosis and Treatment of Common Diseases in Traditional Chinese Medicine Ophthalmology: Symptoms include blurred vision, dark red hemorrhage in the ocular fundus, blurred optic disc margin and edema, attenuated arteries, dilated and tortuous veins, and macular edema; dizziness, chest distress, frequent cough with excessive phlegm; tongue with ecchymosis/petechiae, white greasy coating, wiry pulse; central macular thickness (CMT) = 280 µm; first onset with disease course = 4 weeks; initial best-corrected visual acuity (BCVA) 0.05–0.5; age 40–80 years; stable general condition, well-controlled blood glucose and blood pressure; signed informed consent.

Exclusion criteria

Exclusion criteria: Advanced RVO with best-corrected visual acuity < 0.05; History of anti-VEGF therapy; Recent myocardial infarction, cerebral infarction, or severe opacity of the refractive media that interferes with fundus examination; Comorbid fundus or macular diseases that may cause macular edema; Significant focal capillary non-perfusion in the macular region; Hypersensitivity to any of the study medications.

Design outcomes

Primary

MeasureTime frame
corrected visual acuity ;

Secondary

MeasureTime frame
Chinese Visual Function-Related Quality of Life Scale-25;central macular thickness ;

Countries

China

Contacts

Public ContactNinghua Jiang

Jiaxing Second Hospital

jiangnhnh@163.com13586484565

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026